Apollomics, Inc. announces successful enrollment of first patient in a phase 1 clinical trial of APL-106 (Uproleselan Injection) in China
FOSTER CITY, Calif. And HANGZHOU, ZHEJIANG, China, March 04, 2021 (GLOBE NEWSWIRE) – Announced Apollomics, Inc., an innovative biopharmaceutical company engaged in the discovery and developme…
